Janux Therapeutics, Inc. (NASDAQ:JANX) Stock Holdings Boosted by Janus Henderson Group PLC

Janus Henderson Group PLC raised its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 41.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,562,402 shares of the company's stock after buying an additional 1,038,996 shares during the quarter. Janus Henderson Group PLC owned about 6.79% of Janux Therapeutics worth $190,617,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Lester Murray Antman dba SimplyRich raised its position in shares of Janux Therapeutics by 205.3% during the 4th quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company's stock worth $1,301,000 after purchasing an additional 16,351 shares during the period. abrdn plc acquired a new stake in shares of Janux Therapeutics during the 4th quarter worth approximately $3,430,000. Barclays PLC raised its position in shares of Janux Therapeutics by 496.5% during the 3rd quarter. Barclays PLC now owns 174,061 shares of the company's stock worth $7,907,000 after purchasing an additional 144,883 shares during the period. Legal & General Group Plc raised its position in shares of Janux Therapeutics by 45.3% during the 4th quarter. Legal & General Group Plc now owns 34,540 shares of the company's stock worth $1,849,000 after purchasing an additional 10,776 shares during the period. Finally, Rhumbline Advisers raised its position in shares of Janux Therapeutics by 1.6% during the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock worth $2,043,000 after purchasing an additional 599 shares during the period. Institutional investors and hedge funds own 75.39% of the company's stock.

Janux Therapeutics Price Performance

JANX stock traded up $1.01 on Friday, reaching $24.28. The company's stock had a trading volume of 931,458 shares, compared to its average volume of 868,653. Janux Therapeutics, Inc. has a 52 week low of $22.48 and a 52 week high of $71.71. The company has a market capitalization of $1.44 billion, a P/E ratio of -20.75 and a beta of 3.24. The firm has a fifty day moving average of $28.66 and a two-hundred day moving average of $40.63.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, equities analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on JANX shares. HC Wainwright reiterated a "buy" rating and set a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. Wedbush reiterated an "outperform" rating and set a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Finally, Scotiabank dropped their price target on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $95.25.

Insider Buying and Selling at Janux Therapeutics

In other news, Director Ra Capital Management, L.P. purchased 110,206 shares of the firm's stock in a transaction on Friday, March 7th. The stock was purchased at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the purchase, the director now owns 10,141,287 shares in the company, valued at $314,582,722.74. This trade represents a 1.10% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Andrew Hollman Meyer sold 3,334 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $32.15, for a total value of $107,188.10. Following the transaction, the insider now directly owns 82,139 shares of the company's stock, valued at approximately $2,640,768.85. The trade was a 3.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,001 shares of company stock valued at $313,964. 8.10% of the stock is owned by corporate insiders.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.